3 November 2026 in SSRN Electronic Journal
BackgroundCryptococcus gattii is a primary fungal pathogen capable of causing severe central nervous system infections in apparently immunocompetent hosts. C. gattii meningitis in non-human immunodeficiency virus hosts often presents diagnostic dilemmas, higher rates of neurological complications, and unpredictable therapeutic outcomes. Data regarding clinical trajectories and management outcomes in non-immunocompromised patients remain limited in Asia.Cases presentationsWe describe a case series of eight immunocompetent middle-aged patients diagnosed with culture-confirmed C.gattii meningitis. All patients presented with headaches and low-grade fevers, prompting early lumbar puncture upon admission. Antifungal therapy was promptly initiated following positive cerebrospinal fluid India ink examinations. Despite aggressive induction treatment consisting of amphotericin B combined with either fluconazole or voriconazole, alongside therapeutic daily lumbar punctures for intracranial pressure control, clinical responses varied markedly. Six patients achieved clinical stabilization; however, two experienced progressive deterioration of consciousness, ultimately culminating in irreversible coma.ConclusionC.gattii meningitis poses a substantial clinical challenge in immunocompetent individuals and may carry poor outcomes despite prompt diagnosis and guideline-directed antifungal and decompression therapy. This case series underscores the pressing need for larger prospective studies to identify early prognostic markers, evaluate host immune-inflammatory interactions, and standardize induction and salvage antifungal regimens for this population.